{"groups":[{"description":"Participants with a deleterious mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.","id":"FG000","title":"Rucaparib Cohort A"},{"description":"Participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, or RAD51B.","id":"FG001","title":"Rucaparib Cohort B"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"63"},{"groupId":"FG001","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 83 participants were enrolled across 19 US sites between January 2020 and March 2022. 63 participants were enrolled in cohort A and 20 in cohort B.\n\nCohort A comprised participants with a deleterious mutation in one of the following genes; BRCA1, BRCA2, PALB2, RAD51C, RAD51D.\n\nCohort B comprised participants with a deleterious mutation in one of the following genes: BARD1, BRIP1, FANCA, NBN, RAD51, RAD51B."}